DC-CTL

BIOLOGICAL2 trials

Sponsors

Shenzhen Hornetcorn Bio-technology Company, LTD, Shenzhen University General Hospital

Conditions

Malignant TumorNSCLC

Phase 1

Treatment of Malignant Tumors With Antigen Peptide-specific DC-CTL Cells and Decitabine

Shenzhen University General HospitalMalignant Tumor

Start: 2020-10-30End: 2023-07-28Target: 60Updated: 2020-12-17

Phase 2

Clinical Efficacy and Safety of Dendritic Cytotoxic Lymphocyte(DC-CTL) Cell Infusion in NSCLC Patients

Shenzhen Hornetcorn Bio-technology Company, LTDNSCLC

Start: 2016-05-31End: 2018-12-31Target: 60Updated: 2016-05-09